Horizon Competitors

Summary

HZNPDelisted Stock

USD 100.40 0.13 0.13%

Horizon Pharma PLC competes with Bristol Myers, AbbVie, Merck, Gilead Sciences, and Johnson Johnson; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Horizon Pharma competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Horizon Pharma to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Horizon Pharma competition on your existing holdings.

Specify up to 10 symbols:

Hype

Prediction

Low	Estimated	High
100.40	100.40	100.40

Details

Intrinsic

Valuation

Low	Real	High
87.02	87.02	110.44

Details

Horizon Pharma Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Horizon Pharma and its competitors represents the degree of relationship between the price movements of corresponding delisted stocks. A correlation of about +1.0 implies that the price of Horizon and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Horizon Pharma PLC does not affect the price movement of the other competitor.

	BMY	ABBV	MRK	GILD	JNJ	AMGN	LLY	AZN	SNY	NVS
BMY		-0.58	-0.92	0.84	-0.84	-0.76	-0.84	-0.88	-0.89	-0.88	BMY
ABBV	-0.58		0.55	-0.34	0.61	0.79	0.56	0.54	0.68	0.61	ABBV
MRK	-0.92	0.55		-0.83	0.85	0.81	0.87	0.9	0.93	0.91	MRK
GILD	0.84	-0.34	-0.83		-0.69	-0.49	-0.72	-0.89	-0.74	-0.8	GILD
JNJ	-0.84	0.61	0.85	-0.69		0.8	0.83	0.85	0.86	0.89	JNJ
AMGN	-0.76	0.79	0.81	-0.49	0.8		0.81	0.72	0.85	0.81	AMGN
LLY	-0.84	0.56	0.87	-0.72	0.83	0.81		0.92	0.85	0.95	LLY
AZN	-0.88	0.54	0.9	-0.89	0.85	0.72	0.92		0.85	0.96	AZN
SNY	-0.89	0.68	0.93	-0.74	0.86	0.85	0.85	0.85		0.9	SNY
NVS	-0.88	0.61	0.91	-0.8	0.89	0.81	0.95	0.96	0.9		NVS
	BMY	ABBV	MRK	GILD	JNJ	AMGN	LLY	AZN	SNY	NVS

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

Please upgrade your account to get full access to Macroaxis premium features

High positive correlations

NVS	+ 0.96	AZN
NVS	+ 0.95	LLY
SNY	+ 0.93	MRK
AZN	+ 0.92	LLY
NVS	+ 0.91	MRK
AZN	+ 0.9	MRK

High negative correlations

MRK	- 0.92	BMY
AZN	- 0.89	GILD
SNY	- 0.89	BMY
NVS	- 0.88	BMY
AZN	- 0.88	BMY
LLY	- 0.84	BMY

Risk-Adjusted Indicators

There is a big difference between Horizon Stock performing well and Horizon Pharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Horizon Pharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
BMY	1.31	0.33	0.15	3.11	1.18	(1.47)	2.23	(2.07)	14.39
ABBV	1.02	(0.16)	0.00	(0.72)	0.00	0.00	1.56	(2.11)	18.93
MRK	0.85	(0.26)	0.00	(1.12)	0.00	0.00	1.73	(2.13)	4.89
GILD	0.91	0.22	0.11	0.57	1.00	(0.95)	2.17	(1.82)	10.80
JNJ	0.62	(0.09)	0.00	(0.28)	0.00	0.00	1.40	(1.42)	3.25
AMGN	1.03	(0.25)	0.00	(0.13)	0.00	0.00	1.67	(1.90)	9.43
LLY	1.27	(0.40)	0.00	(0.98)	0.00	0.00	2.35	(3.55)	9.21
AZN	1.05	(0.40)	0.00	28.98	0.00	0.00	1.28	(3.18)	8.50
SNY	0.90	(0.22)	0.00	(2.27)	0.00	0.00	1.74	(1.85)	7.81
NVS	0.69	(0.22)	0.00	(0.88)	0.00	0.00	1.12	(1.98)	6.05

Unable to evaluate fundamental data of [BMY, ABBV, MRK, GILD, JNJ, AMGN, LLY, AZN, SNY, NVS, GSK, RHHBY] at this time. Please try again later

All Fundamental Data

Horizon Pharma Competitive Analysis

The better you understand Horizon Pharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Horizon Pharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Horizon Pharma's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	HZNP	BMY	ABBV	MRK	GILD	JNJ	AMGN	LLY	AZN	SNY
	0.13 100.40 Horizon	0.15 58.78 Bristol	0.06 177.06 AbbVie	2.00 101.16 Merck	0.33 90.49 Gilead	0.39 155.78 Johnson	0.18 294.00 Amgen	0.93 755.00 Eli	1.17 66.40 AstraZeneca	0.14 48.35 Sanofi
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Very Weak	Good	Very Weak	Very Weak	Good	Very Weak	Very Weak	Very Weak	Very Weak	Very Weak
Odds of Financial Distress (Probability Of Bankruptcy)	Dangerous	Low	Low	Low	Very Low	Very Low	Low	Very Low	Low	Very Small
Current Valuation (Equity Enterprise Value)	Over Valued	Under Valued	Over Valued	Fairly Valued	Under Valued	Under Valued	Over Valued	Over Valued	Under Valued	Under Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Buy	Strong Buy	Strong Buy	Buy	Buy	Buy	Strong Buy	Strong Buy	Strong Buy
Trade Advice (90 Days Macroaxis Advice)	Not Rated	Strong Buy	Cautious Hold	Cautious Hold	Buy	Strong Hold	Strong Hold	Strong Sell	Strong Hold	Cautious Hold
Current Ratio	3.96	1.42	0.93	1.46	1.43	1.43	1.68	1.13	0.81	1.3
Net Asset	9.11 B	95.16 B	134.71 B	106.67 B	62.12 B	167.56 B	97.15 B	64.01 B	101.12 B	126.46 B
Profit Margin	0.12	-0.15	0.0922	0.19	0.0045	0.17	0.13	0.2	0.13	0.093
EBITDA	1.11 B	19.42 B	26.36 B	6.91 B	7.61 B	29.34 B	7.9 B	8.57 B	12.98 B	12.6 B
Operating Margin	0.18	0.18	0.29	0.26	0.42	0.25	0.24	0.4	0.2	0.29
Current Valuation	26.87 B	162.7 B	376.49 B	274.43 B	130.61 B	389.04 B	209.71 B	700.3 B	230.96 B	140.02 B
Price To Book	5.1	6.97	51.84	5.64	6.08	5.33	21.03	47.24	5.0	1.59
Retained Earnings	590.01 M	28.77 B	(1000 M)	53.9 B	16.3 B	153.84 B	(26.55 B)	10.31 B	4.52 B	67.5 B
Current Asset	1.11 B	10.41 B	16.31 B	29.76 B	1.18 B	60.21 B	38.52 B	12.57 B	16.01 B	24.93 B
Five Year Return	N/A	2.96	4.33	2.99	3.76	2.59	2.82	1.83	2.99	3.85
Beta	1.01	0.44	0.61	0.41	0.19	0.52	0.6	0.43	0.18	0.45
Number Of Employees	2.19 K	34.1 K	50 K	70 K	18 K	131.9 K	26.7 K	43 K	89.9 K	86.09 K
Shares Outstanding	229 M	2.03 B	1.77 B	2.53 B	1.25 B	2.41 B	537.53 M	899.32 M	3.1 B	2.51 B
Cash Flow From Operations	1.26 B	13.86 B	22.84 B	13.01 B	8.01 B	22.79 B	8.47 B	4.24 B	10.35 B	10.26 B
Annual Yield	N/A	0.0408	0.037	0.0327	0.0342	0.032	0.0306	0.007	0.0226	0.0422
Total Debt	2.56 B	41.46 B	59.38 B	36.27 B	24.99 B	29.33 B	64.61 B	25.23 B	28.62 B	18.42 B
Return On Equity	0.0854	-0.31	0.56	0.28	0.0056	0.21	0.56	0.65	0.17	0.0582
Z Score	7.48	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return On Asset	0.0444	0.0607	0.0772	0.11	0.12	0.084	0.046	0.14	0.085	0.0416
Number Of Shares Shorted	7.1 M	23.42 M	18.13 M	26.23 M	17.74 M	18.11 M	8.82 M	6.62 M	4.63 M	8.12 M
Book Value Per Share	23.2	8.45	3.41	17.58	14.83	29.14	14.0	15.83	26.27	58.1
Current Liabilities	357.55 M	8.02 B	10.89 B	19.2 B	104.89 M	27.75 B	8.67 B	8.23 B	14.87 B	16.82 B
Total Asset	9.11 B	95.16 B	134.71 B	106.67 B	62.12 B	167.56 B	97.15 B	64.01 B	101.12 B	126.46 B
Debt To Equity	0.53	1.32	4.37	0.68	1.3	0.43	N/A	1.58	0.89	0.3
Short Ratio	2.04	2.3	3.61	2.75	3.5	3.13	5.11	2.21	1.3	4.07
Target Price	116.5	59.37	204.74	130.85	96.89	174.89	334.06	992.18	88.27	63.49
Last Dividend Paid	N/A	2.4	6.2	3.04	3.06	4.86	8.88	5.03	2.97	N/A
Shares Owned By Institutions	98.82	78.41	73.43	79.46	88.37	73.11	81.09	83.38	16.75	11.64
Market Capitalization	26.63 B	119.4 B	312.89 B	250.89 B	112.4 B	373.59 B	158.32 B	672.7 B	203.49 B	121.05 B
Price To Earning	32.55	24.88	21.28	18.05	359.42	24.69	22.74	54.92	103.39	7.78
Price To Earnings To Growth	1.0	2.06	0.42	0.069	0.53	0.92	2.12	0.7	0.71	0.76
Price To Sales	6.93	2.52	5.63	3.97	3.97	4.26	4.87	16.46	3.97	2.5
Net Income	521.48 M	8.04 B	4.88 B	365 M	5.61 B	13.33 B	6.72 B	5.24 B	6.9 B	5.4 B
Earnings Per Share	1.88	-3.58	2.87	4.78	0.09	6.05	7.83	9.28	2.07	1.88
Shares Owned By Insiders	1.18	0.11	0.09	0.06	0.11	0.09	0.24	0.15	N/A	N/A
Revenue	3.63 B	45.01 B	54.32 B	60.12 B	27.12 B	85.16 B	28.19 B	34.12 B	45.81 B	46.03 B
Working Capital	2.7 B	9.51 B	(4.84 B)	6.47 B	4.8 B	7.21 B	11.94 B	(1.57 B)	(5.49 B)	6.46 B
Cash And Equivalents	2.13 B	9.12 B	11.88 B	12.69 B	6.14 B	5.37 B	11.48 B	2.07 B	4.52 B	6.9 B
Cash Per Share	9.4	6.21	6.72	4.44	4.9	13.03	21.51	2.97	1.46	2.76
Gross Profit	2.8 B	36.38 B	41.53 B	42.08 B	21.62 B	63.95 B	19.92 B	21.91 B	35.73 B	31.7 B
Day Typical Price	100.55	59.36	178.0	100.8	90.45	155.99	294.94	750.0	66.28	48.46
Accumulation Distribution	0.0127	476884.0	237942.0	759649.0	217786.0	148261.0	60327.88	112969.0	70421.58	51419.52
Market Facilitation Index	1.29	N/A	N/A	N/A	N/A	N/A	0.0	0.0	N/A	N/A
Daily Balance Of Power	0.1008	(0.04)	0.032	0.8879	0.1604	0.3211	(0.14)	0.4663	1.084507	0.1321
Period Momentum Indicator	0.13	(0.09)	0.11	1.98	0.3	0.61	(0.53)	6.99	0.77	0.07
Rate Of Daily Change	1.0	1.0	1.0	1.02	1.0	1.0	1.0	1.01	1.01	1.0
Day Median Price	100.63	59.66	178.47	100.63	90.44	156.09	295.41	747.51	66.22	48.52
Price Action Indicator	(0.16)	(0.92)	(1.35)	1.52	0.2	(0.01)	(1.67)	10.99	0.57	(0.13)
Coefficient Of Variation	(1,338)	550.66	(1,624)	(499.41)	493.19	(1,469)	(1,285)	(509.23)	(374.96)	(617.60)
Mean Deviation	0.7077	1.31	1.02	0.8533	0.9113	0.6214	1.03	1.27	1.05	0.8982
Jensen Alpha	(0.08)	0.3339	(0.16)	(0.26)	0.2173	(0.09)	(0.25)	(0.40)	(0.40)	(0.22)
Total Risk Alpha	(0.46)	0.0375	(0.45)	(0.42)	0.0537	(0.19)	(0.38)	(0.64)	(0.64)	(0.40)
Sortino Ratio	N/A	0.1523	N/A	N/A	0.1107	N/A	N/A	N/A	N/A	N/A
Downside Variance	N/A	2.21	N/A	N/A	1.95	N/A	N/A	N/A	N/A	N/A
Standard Deviation	1.92	1.97	2.02	1.14	1.41	0.7932	1.57	1.78	1.48	1.21
Kurtosis	45.05	10.57	23.17	0.2024	7.15	(0.29)	7.1	1.9	5.96	2.74
Potential Upside	1.13	2.23	1.56	1.73	2.17	1.4	1.67	2.35	1.28	1.74
Treynor Ratio	0.2612	3.11	(0.72)	(1.12)	0.5725	(0.28)	(0.13)	(0.98)	28.98	(2.27)
Maximum Drawdown	16.07	14.39	18.93	4.89	10.8	3.25	9.43	9.21	8.5	7.81
Variance	3.7	3.87	4.08	1.29	1.98	0.6291	2.47	3.17	2.2	1.47
Market Risk Adjusted Performance	0.2712	3.12	(0.71)	(1.11)	0.5825	(0.27)	(0.12)	(0.97)	28.99	(2.26)
Risk Adjusted Performance	(0.05)	0.1454	(0.04)	(0.15)	0.1601	(0.05)	(0.05)	(0.14)	(0.20)	(0.12)
Skewness	(5.92)	2.19	(3.13)	0.2231	1.0	(0.06)	(2.05)	(0.56)	(1.86)	0.5331
Semi Deviation	N/A	1.18	N/A	N/A	0.9968	N/A	N/A	N/A	N/A	N/A
Information Ratio	(0.14)	0.1151	(0.13)	(0.32)	0.1099	(0.23)	(0.16)	(0.27)	(0.35)	(0.27)
Value At Risk	(0.87)	(2.07)	(2.11)	(2.13)	(1.82)	(1.42)	(1.90)	(3.55)	(3.18)	(1.85)
Expected Short fall	N/A	(1.47)	N/A	N/A	(0.95)	N/A	N/A	N/A	N/A	N/A
Downside Deviation	N/A	1.49	N/A	N/A	1.4	N/A	N/A	N/A	N/A	N/A
Semi Variance	N/A	1.39	N/A	N/A	0.9936	N/A	N/A	N/A	N/A	N/A

Horizon Pharma Competition Performance Charts

Five steps to successful analysis of Horizon Pharma Competition

Horizon Pharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Horizon Pharma PLC in relation to its competition. Horizon Pharma's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Horizon Pharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Horizon Pharma's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Horizon Pharma PLC, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Horizon Pharma position

In addition to having Horizon Pharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Hybrid Mix Funds Thematic Idea Now

Hybrid Mix Funds

Funds or Etfs that are made of portfolios of stocks, bonds, or cash instruments with different maturity horizons and characteristics. The Hybrid Mix Funds theme has 42 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Hybrid Mix Funds Theme or any other thematic opportunities.

View All Next

Launch

Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Other Consideration for investing in Horizon Stock

If you are still planning to invest in Horizon Pharma PLC check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Horizon Pharma's history and understand the potential risks before investing.

	Stocks Directory Find actively traded stocks across global markets
	Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences
	Technical Analysis Check basic technical indicators and analysis based on most latest market data
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges
	CEOs Directory Screen CEOs from public companies around the world
	Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC